Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQLE | Q14534 | 7/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.68 |
| ▸ | ICMT | O60725 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096216 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL17554341 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL8622512 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL24940711 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL8625008 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL24940873 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL16221426 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL24940909 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL3096208 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL5603630 | 1.00 | SQLE (0.80) | SQLEKMT2AMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0571928-A1 | Acyclic Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | Bristol-Myers Squibb Company (US) | 1993-12-01 | — | — | EP | claimed |
| EP-0476493-A1 | Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | Bristol-Myers Squibb Company (US) | 1992-03-25 | — | — | EP | claimed |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | FARNEX INCORPORATED (JP) | 2016-03-10 | — | — | US | disclosed |
| EP-2992910-A1 | ADHESION PREVENTING AGENT | Farnex Incorporated (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| US-5428028-A | Method for lowering cholesterol employing a phosphonomethylphosphinate squalene synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1995-06-27 | — | — | US | disclosed |
| US-5393776-A | Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| US-5391765-A | Lowers low density lipoproteins | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0601573-A1 | Alpha-phosphonocarboxylate squalene synthetase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-06-15 | — | — | EP | disclosed |
| US-5157027-A | Anticholesterol agents | E. R. SQUIBB & SONS, INC. (US) | 1992-10-20 | — | — | US | disclosed |
| US-5107011-A | Intermediates for anticholesterol agents | E. R. SQUIBB & SONS, INC. (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0476493-A1 | Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | Bristol-Myers Squibb Company (US) | 1992-03-25 | — | — | EP | disclosed |
| US-5025003-A | Anticholesterol agents | E. R. SQUIBB & SONS, INC. (US) | 1991-06-18 | — | — | US | disclosed |
| EP-0418814-A2 | Isoprenoid phosphinylformic acid squalene synthetase inhibitors and method for preparing the same | E.R. SQUIBB & SONS, INC. (US) | 1991-03-27 | — | — | EP | disclosed |
| US-4924024-A | ANTICHOLESTEROL AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0356866-A2 | Phosphorus-containing squalene synthetase inhibitors and method | E.R. SQUIBB & SONS, INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| US-4871721-A | HYPOCHOLESTEROLEMIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0324421-A2 | Phosporus-containing squalene synthetase inhibitors, new intermediates and method | E.R. Squibb & Sons, Inc. (US) | 1989-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067208-A1 | ADHESION PREVENTING AGENT | EPCAM, ICAM1, VCAM1 | SQLE 3034/4885KMT2A 2693/4885MAPT 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.